Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 42

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Pancreatic neuroendocrine tumour

Not recruiting

Study of Ramucirumab and Dacarbazine for Patients with Progressive Metastatic Pancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Neuroblastoma+5

Not recruiting

Study of Nivolumab with Chemotherapy for Children and Teenagers with Refractory or Relapsing Solid Tumors or Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Capecitabine
  • Sponsor:Centre Oscar Lambret

Adrenal adenoma

Not recruiting

Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion Due to Adrenal Adenoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone Bp
  • Sponsor:Medical University Of Vienna

Neuroendocrine carcinoma metastatic

Not recruiting

Study of AdVince (Modified Adenovirus) Treatment Through Hepatic Artery Injection in Patients with Advanced Neuroendocrine Neoplasms

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Adenovirus C Serotype 5 With E1 Gene Controlled By Chromogranin A Promoter And Hexon Modified With Protein Transduction Domain Motif
  • Sponsor:Uppsala University

Diabetic neuropathy+1

Not recruiting

Study on the Effectiveness of ODM-111 and Paracetamol for Chronic Pain in Patients with Diabetic Peripheral Neuropathy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111
  • Sponsor:Orion Corporation

Thyroid cancer

Not recruiting

Study of Cabozantinib in Adults with Progressive Thyroid Cancer Who Did Not Respond to Previous Treatment with Radioactive Iodine and VEGFR Therapy

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Adrenoleukodystrophy

Not recruiting

Study on the Effects of Leriglitazone for Adult Men with Cerebral Adrenoleukodystrophy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leriglitazone
  • Sponsor:Minoryx Therapeutics S.L.

Type 1 diabetes mellitus

Not recruiting

Study on Ixekizumab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Ixekizumab
  • Sponsor:NU Hospital Group-Vaestra Goetalandsregionen

Neuroendocrine carcinoma metastatic

Not recruiting

Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Precocious puberty

Not recruiting

Study on Slowing Advanced Puberty in Girls Using Metformin, Pioglitazone, and Spironolactone

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Metformin
  • Sponsor:Hospital Universitari De Girona Doctor Josep Trueta

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-001 for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-001
  • Sponsor:Viridian Therapeutics Inc.

Diabetic retinal oedema

Not recruiting

Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.